BioLife Solutions: Strong Financial Performance and Strategic Focus Justify Buy Rating

TD Cowen analyst Brendan Smith maintained a Buy rating on BioLife Solutions yesterday and set a price target of $33.00.

Brendan Smith has given his Buy rating due to a combination of factors that highlight BioLife Solutions’ strong financial performance and strategic decisions. The company exceeded expectations in the third quarter with revenues of $28 million, surpassing the consensus estimate of $26 million, primarily due to robust cell processing revenue. This outperformance is supported by BioLife’s exposure to commercial therapies and late-stage clinical trials, which mitigate risks associated with growth projections.
Furthermore, the divestment of the evo Cold Chain Logistics subsidiary reflects management’s focus on core strengths, enhancing the company’s financial profile. The updated revenue guidance for FY25, accounting for the sale of evo, projects revenues of $95-96 million, indicating significant growth. Additionally, the company anticipates improved gross margins and a reduction in net loss, with an expansion of adjusted EBITDA margins into the 30% range long-term. These factors, along with the raised price target to $33, underscore the positive outlook for BioLife Solutions, justifying the Buy rating.